SCHEMBL4145107

SCHEMBL4145107

CC(C)(C)C(OC1CC(C2=C3C=NC=C[N+]3(Cl)C(c3cccc(OCc4ccccc4)c3)=N2)C1)C(=O)[O-]

nearest known ligand 0.32

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 5/20 0.32
IGF1R P08069 3/20 0.32
MRGPRX4 Q96LA9 1/20 0.32
MAOB P27338 1/20 0.31
ADAMTS4 O75173 1/20 0.31
CTSA P10619 1/20 0.31
HDAC4 P56524 1/20 0.31
JAK2 O60674 1/20 0.31
JAK1 P23458 1/20 0.31
SLC16A3 O15427 1/20 0.31
SLC16A1 P53985 1/20 0.31
MCTS1 Q9ULC4 1/20 0.31
NR4A2 P43354 1/20 0.30
PDK1 Q15118 1/20 0.30
PDK2 Q15119 1/20 0.30
PDK3 Q15120 1/20 0.30
PDK4 Q16654 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2463550 0.91 DHODH (0.33) DHODHIGF1RMRGPRX4MAOBCTSA
SCHEMBL2459738 0.85 MAOB (0.37) DHODHIGF1RMRGPRX4MAOBHDAC4
SCHEMBL2463346 0.82 IGF1R (0.35) IGF1RMRGPRX4HDAC4JAK2JAK1
SCHEMBL2459920 0.82 IGF1R (0.38) IGF1RMRGPRX4MAOBHDAC4JAK2
SCHEMBL2460369 0.81 IGF1R (0.38) IGF1RMRGPRX4
SCHEMBL2459426 0.80 BRD4 (0.36) MRGPRX4MAOBHDAC4JAK2JAK1
SCHEMBL2460301 0.79 IGF1R (0.35) IGF1RMAOBJAK2JAK1
SCHEMBL2465897 0.79 F9 (0.34) IGF1RMRGPRX4MAOB
SCHEMBL2460497 0.78 JAK2 (0.40) IGF1RMRGPRX4MAOBHDAC4JAK2
SCHEMBL2460207 0.78 NR1H2 (0.35) IGF1RMRGPRX4HDAC4JAK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors OSI PHARMACEUTICALS, INC. 2009-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors IGF1R, IRS1, IGFBP1 DHODH 3525/4885IGF1R 1/4885MRGPRX4 1767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.